Mineralys Therapeutics, Inc. (MLYS) P/B ratio
Mineralys Therapeutics, Inc. (MLYS) trades at 1.5× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 3.8×. That is 21.5% higher than the 3.1× of fiscal 2024. Figures as of 18 Nov 2026, 04:23 UTC, from Yahoo Finance.
Key facts
- P/B ratio today
- 1.5×
- P/B ratio, fiscal 2025
- 3.8×
- Change on fiscal 2024
- +21.5%
- Highest on record
- 3.8×fiscal 2025
- Lowest on record
- 1.3×fiscal 2023
- Fiscal years on record
- 32023–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Mineralys Therapeutics, Inc. P/B ratio, in more detail
Today's figure is 60.1% below the fiscal 2025 year-end.
Across the 3 fiscal year-ends on record (2023–2025), the highest was 3.8× in fiscal 2025 and the lowest 1.3× in fiscal 2023. Today's P/B ratio is higher than at 33% of the 3 fiscal year-ends on record; their median is 3.1×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Mineralys Therapeutics, Inc. P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 1.5× | — | $14.48 | — | |
| 2025 | 3.8× | 21.5% up | $36.29 | $9.56 | |
| 2024 | 3.1× | 142.1% up | $12.31 | $3.94 | |
| 2023 | 1.3× | — | $8.60 | $6.66 | |
| 2022 | — | — | — | -$1.34 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
Mineralys Therapeutics, Inc., figure by figure
- Mineralys Therapeutics, Inc. market cap
- Mineralys Therapeutics, Inc. revenue
- Mineralys Therapeutics, Inc. earnings
- Mineralys Therapeutics, Inc. earnings per share (EPS)
- Mineralys Therapeutics, Inc. P/E ratio
- Mineralys Therapeutics, Inc. P/S ratio
- Mineralys Therapeutics, Inc. free cash flow
- Mineralys Therapeutics, Inc. operating margin
- Mineralys Therapeutics, Inc. dividend
- Mineralys Therapeutics, Inc. shares outstanding
- Mineralys Therapeutics, Inc. total debt
- Mineralys Therapeutics, Inc. cash on hand
- Mineralys Therapeutics, Inc. total assets
- Mineralys Therapeutics, Inc. return on equity (ROE)
- Mineralys Therapeutics, Inc. return on invested capital (ROIC)
Mineralys Therapeutics, Inc. (MLYS) overview: price, valuation and scorecard
Mineralys Therapeutics, Inc. P/B ratio: questions and answers
What is Mineralys Therapeutics, Inc.'s P/B ratio?
Mineralys Therapeutics, Inc. (MLYS) trades at 1.5× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 3.8×. That is 21.5% higher than the 3.1× of fiscal 2024.
Is Mineralys Therapeutics, Inc.'s P/B ratio high or low compared with its own history?
Today's P/B ratio is higher than at 33% of the 3 fiscal year-ends on record; their median is 3.1×.
What are the highest and lowest P/B ratio figures on record for Mineralys Therapeutics, Inc.?
Across the 3 fiscal year-ends on record (2023–2025), the highest was 3.8× in fiscal 2025 and the lowest 1.3× in fiscal 2023.
How is Mineralys Therapeutics, Inc.'s P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Mineralys Therapeutics, Inc. (MLYS) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/MLYS/pb-ratio
Underlying data: Yahoo Finance.